These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16550733)

  • 41. Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.
    Fels H; Steward R; Melamed A; Granat A; Stanczyk FZ; Mishell DR
    Contraception; 2013 Jun; 87(6):732-7. PubMed ID: 23352800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
    Jacobsen LV; Vouis J; Hindsberger C; Zdravkovic M
    J Clin Pharmacol; 2011 Dec; 51(12):1696-703. PubMed ID: 21228406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent.
    Crean CS; Tompson DJ; Buraglio M
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):847-53. PubMed ID: 24040852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
    Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.
    Wong SL; O'Dea RF; Dube LM; Awni WM
    J Clin Pharmacol; 1998 Jul; 38(7):642-8. PubMed ID: 9702850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
    Crauwels HM; van Heeswijk RP; Buelens A; Stevens M; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):118-28. PubMed ID: 24161160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
    Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
    Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
    Robertson SM; Luo X; Dubey N; Li C; Chavan AB; Gilmartin GS; Higgins M; Mahnke L
    J Clin Pharmacol; 2015 Jan; 55(1):56-62. PubMed ID: 25103957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
    Elomaa K; Ranta S; Tuominen J; Lähteenmäki P
    Contraception; 2001 Jan; 63(1):13-8. PubMed ID: 11257243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
    Granfors MT; Backman JT; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.
    Migoya E; Larson P; Bergman A; Miller J; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2011 Sep; 51(9):1319-25. PubMed ID: 21209231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
    Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.
    Saano V; Glue P; Banfield CR; Reidenberg P; Colucci RD; Meehan JW; Haring P; Radwanski E; Nomeir A; Lin CC
    Clin Pharmacol Ther; 1995 Nov; 58(5):523-31. PubMed ID: 7586946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.
    Loi CM; Stern R; Koup JR; Vassos AB; Knowlton P; Sedman AJ
    J Clin Pharmacol; 1999 Apr; 39(4):410-7. PubMed ID: 10197300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
    Zurth C; Schuett B; Casjens M; Ludwig M; Waellnitz K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):245-55. PubMed ID: 27136904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.